Clint A. Stalnecker

University of North Carolina at Chapel Hill

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer”.

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Nature(2024)10.1038/s41586-024-07379-z

N/A

3.9DataRank · unranked

182 citations

Jingjing Jiang, Tanner C. Dalton, Álvaro Curiel‐García, A. Cole Edwards, Yingyun Wang +61 more

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen

Molecular Oncology(2021)10.1002/1878-0261.12951

N/A

0DataRank · unranked

8 citations

Craig M. Goodwin, Kotryna Seip, Bylgja Hilmarsdóttir, Solveig Pettersen, Clint A. Stalnecker +8 more

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer

Cancer Research(2022)10.1158/0008-5472.can-22-0391

N/A

0DataRank · unranked

163 citations

Andrew M. Waters, Jennifer E. Klomp, Sehrish Javaid, Kirsten L. Bryant, Clint A. Stalnecker +19 more

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

Genes & Cancer(2023)10.18632/genesandcancer.231

N/A

0DataRank · unranked

9 citations

Jennifer E. Klomp, Clint A. Stalnecker, Craig M. Goodwin, Yanzhe Gao, Gaith N. Droby +5 more

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

UNC Libraries(2024)10.17615/2caa-2659

N/A

0DataRank · unranked

24 citations

Daniel Zeitouni, Clint A. Stalnecker, Haoqiang Ying, Erik S. Knudsen, Guofang Zhang +26 more

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.

UNC Libraries(2024)10.17615/s0p7-tg86

N/A

0DataRank · unranked

12 citations

Jennifer E. Klomp, Bjoern Papke, Craig M. Goodwin, Andrew P. Beelen, Clint A. Stalnecker +19 more

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer

Science Translational Medicine(2025)10.1126/scitranslmed.adt5511

N/A

0DataRank · unranked

10 citations

Francesca Paradiso, Clint A. Stalnecker, Benson Chellakkan Selvanesan, Fredrik I. Thege, David H. Peng +40 more

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

Cancer Research(2025)10.1158/0008-5472.can-25-1835

N/A

0DataRank · unranked

5 citations

Haley Todd, Grace Goodhart, Wen-Hsuan Chang, Amber M. Amparo, Rachel Bridgens +20 more

The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled

Journal of Biological Chemistry(2020)10.1016/s0021-9258(17)49889-9

N/A

0DataRank · unranked

6 citations

Sekar Ramachandran, Thuy‐Tien T. Nguyen, Clint A. Stalnecker, Richard A. Cerione, Jon W. Erickson +1 more

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

UNC Libraries(2025)10.17615/j33x-8959

N/A

0DataRank · unranked

0 citations

Channing J. Der, Kirsten L. Bryant, Jennifer E. Klomp, Yanzhe Gao, Clint A. Stalnecker +5 more